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FOREWORD 
This report is the result of a request of the Swiss Commission for 
Vaccination (EKIF) to the Groupe de Recherche sur la Santé des 
Adolescents (GRSA) to perform a modeling of the HPV 
seroconversion among Swiss females after introducing the HPV 
vaccine. This research has been financed by GlaxoSmithKline AG, 
Switzerland 
In the preliminary discussions, the EKIF had basically two questions 
that needed to be answered: 
• at what age should Swiss females be vaccinated? 
• up to what age should a catch-up vaccine be administered? 
There is a clear consensus in the literature regarding the first question: 
females need to be vaccinated before beginning sexual activity. 
Although this fact is still under discussion in many countries, the 
current recommendations both from the American Advisory 
Committee on Immunization Practices and the American Cancer 
Society are to start vaccinating at ages 11-12. For this reason, it was 
decided that our model would be based on an hypothetical vaccination 
program that would be implemented at age 12 in Switzerland. The 
first question being solved, the principal interest of the EKIF was to 
have an answer to the catch-up question. This report focuses mainly 
on this point. 
As the HPV vaccines currently marketed are mainly directed towards 
the prevention of cervical precancerous lesions and cancer, only the 
expected effect on the infection rates of HPV types 16 and 18 are 
analyzed in this report. 
Furthermore, as there is evidence that the vaccination of both genders 
has little benefit over vaccinating females only, this report refers only 
to the potential impact of vaccinating females in Switzerland. 
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SUMMARY 
Human papillomavirus (HPV) is a sexually transmitted infection (STI) of particular interest 
because of its high prevalence rates and casual association with cervical cancer. HPV 
infection is extremely common in sexually active adolescents and young adults, and the 
acquisition of HPV occurs soon after sexual debut as sexual intercourse (both vaginal and 
anal) is the primary route of genital HPV infection. 
Sexual behavior is the most constant predictor of acquiring HPV infection. Although many 
risk factors have been described in the literature, number of sexual partners, together with 
having had a new sex partner in the 3 to 8 months prior to the visit are the most consistent. 
Additionally, the characteristics of the sexual partner’s behavior are also important: it has 
been described that partner’s promiscuity (defined as number of sexual partners) is the most 
important risk factor. 
HPV vaccines are characterized as therapeutic or prophylactic. Although the former ones are 
in very early stages of development and have shown limited success, the later have 
demonstrated high efficacy. However, the duration of the vaccine’s protection is unclear and 
results to date indicate a sustained efficacy up to 5 years. As HPV acquisition occurs soon 
after sexual initiation, the vaccine would have greater effectiveness if administered to young 
adolescents before the onset of sexual activity. Evidence to date also indicates that 
vaccinating both genders had little benefit over vaccinating females only. 
Two questions arise regarding HPV vaccination: 
1. At what age should the vaccine be introduced in a routine schedule? 
2. Up to which age should the vaccine be recommended in catch-up form? 
To answer the first question, it is clear that the vaccine has to be implemented before the onset 
of sexual activity. Both the American Advisory Committee on Immunization Practices 
(ACIP) and the American Cancer Society (ACS) recommend to vaccinate females at age 11-
12 years 
To tackle the second question, the ACIP also recommends catch-up vaccination for females 
aged 13 to 26 years who have not received the vaccine or who have not completed the full 
vaccine series. On the other hand, the ACS recommends catch-up vaccination up to age 18 
because there are insufficient data for or against vaccination among females aged 19-26 years. 
Vaccination beyond age 26 or for males is not recommended  
Objective 
The objective of this report is to create a mathematical model using Swiss data to explore the 
theoretical HPV infection and vaccine coverage rates in the female Swiss population using 
different scenarios that take into account both the upper catch-up age limit and three different 
efficacy time-frames (5 years, 10 years, and lifelong). In all cases, the routine vaccination 
program would start at age 12. 
Model 
The model is based on the classic SIR approach. Individuals are classified as either 
Susceptible of being infected (state S), Infective (I), or in Remission (R). Two additional 
states, Vaccinated (V) and Vaccinated-Infective (VI) are also considered to take into account 
the effect of a vaccination program. The principle of the model is to follow year after year a 
complete population made of individuals of ages 1 to 100 of both sexes. Each year, 
individuals are classified into one of the 5 mutually-exclusive states (S, I, R, V, VI). Possible 
transitions from one state to another are described as difference equations. Different types of 
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vaccination programs can be implemented to study their short- and long-term impact onto the 
population. Vaccination programs can include vaccination at a particular age, one or several 
boosters, and a catch-up procedure up to a given age, with or without booster. The impact of 
each vaccination scenario can be studied after a given number of years. It is also possible to 
obtain endemic results. 
Results / Conclusions 
Regarding the results of this report, the specific conclusions are: 
1. Overall, and both from the reduction of the infection rate and the vaccination coverage 
rate points of view, any catch-up is better than no catch-up at all. However, our model 
indicates that a catch-up to age 18 or to age 20 would represent a very small 
difference. The same would be true between a catch-up to age 22 or to age 25, 
although the later would result in better coverage and infection rates than the former. 
This statement is independent of the efficacy of the vaccine and of whether or not a 
booster is implemented. 
2. In the case of a 5-year efficacy vaccine (which is the current case as far as we know) 
without booster, the maximum expected vaccination coverage of 85% would only be 
maintained up to age 16/17, both in a 15 or 30-year horizon and independently of 
whether there is a catch-up or not. Under the same circumstances, half of the women 
aged 22 would still be protected. In a 15-year perspective, some coverage (23%) 
would still be expected among women aged 30 with a catch-up to age 18/20, while 
with a catch-up to age 22/25 the same coverage would be observed up to age 35. In a 
30-year perspective, the same coverage rate would be observed up to age 40 (7%) 
independently of catch-up. In the case of a catch-up to age 22/25, the coverage would 
be extended to age 50, although it would be minimal (<5%). 
3. In the case of a 5-year efficacy vaccine including 2 boosters (at ages 17 and 22), a 
85% vaccination coverage would be assured, in any case, up to age 25. For a 15-year 
horizon, any catch-up would still maintain a 50% protection among women aged 30. 
A catch-up to age 22/25 would still maintain a protection slightly below 40% among 
women aged 35. In 30 years, this vaccination option would still maintain protection 
rates of 62%, 36% and 21% at, respectively, ages 30,35 and 40 years independently of 
catch-up. A catch-up to age 22/25 would still maintain some coverage (8%) at age 50. 
4. In the case of a 10-year efficacy vaccine without booster (that could be overlapped to a 
5-year efficacy vaccine with one booster at age 17), the maximum expected coverage 
would be maintained up to age 22 and would still be slightly above 60% at age 25 in 
any case. For a 15-year horizon, any catch-up would imply a coverage just under 40% 
at age 30 and also at age 35 but in this later case only for those with a catch-up to age 
22/25. In 30 years, independently of catch-up, a vaccine coverage of 36, 21 and 12%, 
respectively, would be expected for ages 30, 35 and 40. A catch-up to ages 22/25 
would only add a small coverage (8%) at age 50. 
5. In the case of a 10-year efficacy vaccine that would include a booster 10 years later 
(age 22), the situation is different depending on the chosen horizon. In 15 years, 
maximum coverage up to age 25 would be assured in any case. Any catch-up would 
result in a 67% coverage at age 30, while a catch-up to ages 22/25 would imply a 65% 
coverage at age 35. In a 30 years perspective, the maximum projected coverage would 
be maintained up to age 30. Any option would result in a 62% coverage at age 35 and 
36% at age 40. With a catch-up to ages 22/25, 23% of the women aged 50 would still 
be protected. 
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6. In the case of a lifelong efficacy vaccine, in 15-years time the projected maximum 
coverage would reach age 25. Any catch-up would still protect 74% of women aged 
30 and a catch-up to ages 22/25 would result in a 72% coverage at age 35. In 30 years, 
any vaccination option would result in a maximum expected coverage up to age 40, 
while a catch-up to ages 22/25 would add a 72% coverage at age 50. 
Recommendation 
At the present time it is difficult to give clear recommendations about the best vaccination 
program option because we lack information on one of the main factors influencing this 
decision: the duration of the vaccine efficacy. To date, there is only evidence of a 5 year 
efficacy (1;2). 
From this standpoint, the current recommendation would be to implement a vaccination 
program among girls aged 12 years with a catch-up to age 22 years, since a longer catch-up 
time (up to age 25) would mean an extremely small difference. 
However, this recommendation should be reviewed in five years. At that point in time, we 
will be facing two possible situations: 
1. There will be evidence of a longer duration of the vaccine’s efficacy (up to 10 years) 
and no changes in the vaccination program would be needed. 
2. There will be no evidence of an efficacy duration beyond 5 years and a decision 
regarding booster implementation will need to be taken. 
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BACKGROUND 
Human papillomavirus (HPV) is a sexually transmitted infection (STI) of particular interest 
because of its high prevalence rates and casual association with cervical cancer (3). HPV 
infection is extremely common in sexually active adolescents and young adults (1;3), and the 
acquisition of HPV occurs soon after sexual debut (1;4) as sexual intercourse (both vaginal 
and anal) is the primary route of genital HPV infection (5). Even adolescents who abstain 
from sexual intercourse but not other forms of sexual behavior may still be infected because 
HPV is transmitted through skin-to-skin contact (6), although the risk of transmission through 
digital-genital and oral-genital contact seems to be minimal (5). Women under age 25 years 
have the highest acquisition of high risk HPV types per year (7). 
In the United States, HPV has become the most common STI among adolescent and young 
women in the past 2 decades (4). It is estimated that 3 out of 4 new HPV infections occur 
among 15-24-year-olds (8). However, incidence appears to decrease after age 30 years 
(4;5;9;10). 
Although most HPV infections result in no clinical changes, some experts consider that the 
detection of any HPV indicates undetectable changes in the epithelium (1). 
Prevalence 
Swiss data based on a clinical sample of adolescents aged 14 to 20 years show a prevalence of 
14.2% for any HPV type (11). American data for women aged 18-35 years show a baseline 
prevalence of 43% and a cumulative prevalence at follow-up of 54% (12). Another US-based 
study among women aged 18-25 years showed an overall prevalence of 27%, that declined 
with age (13). In the United Kingdom, HPV prevalence rates decline from 19% for those 
under age 25 to less than 3% for those aged 40 and above (14). Moreover, a prevalence of 
14% was reported among those having had only one lifetime sexual partner (13). Another 
American study found an HPV prevalence of 64% in a clinical sample of 12-20 year-olds 
(15). Among 60 14-17year-olds, Brown et al. (3) found a baseline prevalence of 45% and a 
cumulative one of 82%, with higher rates for high risk HPV types (39%) compared to low 
risk ones (20%). Other studies have also reported higher prevalence rates for high risk HPV 
infections (22%) than low risk infections (15%) (16), while others (10) found that high risk 
types has a slightly lower prevalence (15.2%) than low risk types (17.8%). 
Incidence 
In general, oncongenic (high risk) HPV infections also show higher incidence rates than 
nononcogenic (low risk) HPV infections (5;12). The cumulative 24-month incidence of HPV 
for a sample of women with a mean age of 19 years was 39% both for those sexually active at 
enrollment and for those who started sexual activity during follow-up. Moreover, even 
virginal women showed a rate of 8% (17). Other studies have found a cumulative 36-month 
incidence of 43% (18). 
In the United Kingdom, Woodman et al. (19) found a cumulative risk of HPV infection at 3 
years of 44% and of 60% at 5 years. A study among females aged 13-21 years in California 
reported that 17% acquired the infection in the first year and 55% after 3 years (20). A 
Canadian study (21) found an overall incident HPV infection rate of 11% among women aged 
15-49 years, with the highest rate (25%) among those aged 15-19 years (Table 1). 
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Table 1. Frequency of HPV infection 
Author, year, country 
(ref) 
Sample N Age Response 
rate 
Follow-up Measure Result [95% CI] 
Ho et al., 1998, USA (18) Convenience 608 20+/-3 Not mentioned 2.2 years (mean) Prevalence 
Cumulative 36-months incidence 
26% (at baseline) 
43% [36/49] (among HPV(-) at 
enrollment) 
Woodman et al., 2001, 
UK (19) 
Clinical 1075 15-19 
Median:16 
53% 29 months (median) Prevalence 
Cumulative risk at 3 years 
Cumulative risk at 5 years 
37.9% 
44% [40/48] 
60% 
Lüdicke et al., 2001, 
Switzerland (11) 
Clinical 134 14-20 Not mentioned None Prevalence 14.2% 
Giuliano et al., 2002, 
USA  
Clinical 331 18-35 
Mean: 24.2 
42.1% 10 months (median) Prevalence 42.9% (baseline) 
53.5% (cumulative) 
Winer et al., 2003, USA 
(17) 
Random 603 18-20 20% 41.2 months (mean) Cumulative 24-months incidence Overall: 32.3% [28.0/37.1] 
Sexually active*: 38.8% [33.3/45.0] 
Virgins*: 38.9% [29.4/50.3] 
Virgin**: 7.9% [3.5/17.1] 
Richardson et al., 2003, 
Canada (16) 
Clinical 621 17-42 
Mean: 23 
Not mentioned 24 months  Prevalence 21.8% (high risk) 
14.8% (low risk) 
Sellors et al., 2003, 
Canada (21) 
Random 253 15-49 50.6% 14 moths (mean) Incidence 11.1% 
Peto et al., 2004, UK (14) Clinical 785 15-24 Not mentioned Cohort Prevalence 23% (overall) 
19% (High risk HPV) 
Tarkowski et al., 2004, 
USA (15) 
Clinical 312 12-19 
Mean: 16.1 
>85% None Prevalence 64% 
Brown et al., 2005, USA 
(3) 
Clinical 60 14-17 
Mean: 15.3 
Not mentioned 2.2 years (median) Prevalence 28.3% (at enrollment) 
81.7% (cumulative) 
Manhart et al., 2006, 
USA (13) 
Population-
based 
3262 18-25 
Mean: 21.7 
Not mentioned None Prevalence 26.9% [23.7/30.1] 
Winer et al,, 2006, USA 
(22) 
Convenience 210 18-22 
Mean: 19.3 
86.4% 33.9 months(mean) Cumulative 12-momth incidence 37.2% [27.2/49.4] 
Dunne et al., 2007, USA 
(10) 
Representative 
sample 
1921 14-59 77% None Prevalence 23.3% [23.3/30.9] (14-59 year-olds) 
24.5% [19.6/30.5] (14-19 year-olds) 
*At enrollment / ** Throughout the study period 
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HPV types 
More than 100 different HPV types have been identified and approximately 40 infect genital 
epithelia. About half of them are classified as high risk or oncogenic because of their association 
with cervical cancer. Currently HPV types 16,18,31,33,35,39,45,51,52,56,58,59,68,73 and 82 are 
included in this group (4). 
Infections with multiple HPV types are common, ranging from 40% (10) to almost two thirds of 
HPV-positive women (13). In their study of 227 HPV-positive women, Molano et al. (23) 
reported that half of the infections were multiple. Among women under 25, 40% were single 
infections, 30% included 2 types and 30% three types or more. In most studies, HPV16 was the 
most commonly identified type (13;15-17;19;23;24) (Table 2). 
Table 2. Frequency of HPV-16 and HPV18. 
Author, year (ref) Measure HPV-16 
[95% CI] 
HPV-18 
[95% CI] 
Ho et al., 1998 (18) Cumulative 24-month incidence 7% [4/9] 4% [3/6] 
Woodman et al., 2001 (19) Cumulative risk at 3 years 10.5 [8.3/12.7] 6.6 [4.8/8.4] 
Giuliano et al., 2002 (13) Period prevalence 14.5% 1.8% 
Molano et al., 2003 (23) Prevalence 16% 5% 
Richardson et al., 2003 (16) Prevalence 7.0% 3.1% 
Winer et al., 2003 (17) Cumulative 24-month incidence 10.4% [7.8/13.8] 4.1% [2.6/6.4] 
Peto et el., 2004 (14) Prevalence (ages 14-24) 9.0% - - 
Tarkowski et al., 2004 Prevalence 10.2% 5.1% 
Brown et al., 2005 (3) Prevalence 11.6% 4.8% 
Manhart et al., 2006 (13) Prevalence 5.8% 2.2% 
Dunne et al., 2007 (10) Prevalence 1.5% [0.9/2.6] 0.8% [0.4/1.5] 
Clearance 
Median time to clearance is defined as the time required for 50% of the women to have cleared 
the HPV infection (12). Most genital HPV infections are transient, asymptomatic and resolve 
without treatment (2). Although the incidence of HPV infection is high, most infections (up to 
90%) are spontaneously cleared by the immune system (1;2;6). An American study describes that 
at 12 months after the infection only 30% of women were still infected, dropping to only 9% at 
24 months (18). Another study carried in Colombia (23) reported that 23% of infections were still 
present at 1 year and 7% at 5-years follow-up. In an American study, the time frame for clearance 
was longer for oncogenic HPV infections (9.8 months) than for nononcogenic ones (4.3 months) 
(12). These results are similar to other studies (3;23). The median time to clearance for HPV-16 
was reported to be of 8.5 months (12). Additionally, the risk of not clearing a high risk HPV 
increases with age (7). 
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Persistence 
Persistence can be broadly defined as the detection of the same HPV type two or more times with 
a given time interval between the examinations (9). The longer an infection persists, the more 
likely it is to continue to persist (18). Persistent infection with high risk HPV types is the most 
important risk factor for cervical cancer precursor lesions (1). Risk factors for persistent HPV 
infection (over 6 months) were older age, infection with multiple HPV types and infection with a 
high-risk type HPV, while on the other hand, cigarette smoking seems to be protective against 
persistent infection (18). 
Risk factors 
Sexual behavior is the most constant predictor of acquiring HPV infection (2). Although many 
risk factors have been described in the literature, number of sexual partners 
(1;2;10;11;13;15;17;18;20-22;25;26), together with having had a new sex partner (1;10) in the 3 
months (12) or 5-8 months prior to the visit (17) are the most consistent.  
Other described risk factors are more inconsistent. Younger age (1;2;10;13;18) and early age at 
first intercourse (2;13;25) have been described as risk factors, but other studies found no 
association with them (11;13;15;26), probably because younger age and early age at first 
intercourse are correlated with a higher number of sexual partners. 
Some authors have reported a history of sexually transmitted infection as a risk factor (20;25), 
although others (13;17;21) have not confirmed it. 
The effect of smoking on HPV acquisition is unclear (5): some describe it as a risk factor (17), 
others found no association (11;13;15;21;26). The same is true for alcohol and drug use related to 
sexual behaviors, with some describing them as risk factors (13;18;25) and others finding no 
association (15;17). 
Most studies assessing the relationship between HPV infection and condom use have failed to 
demonstrate a protective effect (5). Correct and consistent condom use was not significantly 
associated with HPV infection in several studies (13;17). In their meta-analysis, Manhart and 
Koutsky (27) did not find consistent evidence that condom use prevented HPV infection, 
although it seemed to prevent HPV-related diseases. Nevertheless, consistent condom use by 
their partners seems to reduce (but not eliminate) the risk of HPV infection among women (22). 
Association between HPV infection and hormonal contraceptive use is also inconsistent (5): 
although some indicate that current use of oral contraceptives is a risk factor (17), others found 
that the association was not significant (11;21;26) and still others that it was a protective factor 
(20). 
A study found that a high frequency of vaginal sex was related to HPV infection (18), but others 
found that the association was not significant (11). Other risk factors described by single studies 
but not confirmed are: race (African-American) (25) or belonging to an ethnic minority (18); 
never having been married (10;13); douching (15); or anal sex (18). 
The characteristics of the sexual partner’s behavior are also important. It has been described that 
partner’s promiscuity (defined as number of sexual partners) is the most important risk factor 
(1;2;17;18;22;25). However, other factors such as partner’s age, partner’s race or male 
circumcision are not consistent (5;15;17;25;26) (Table 3). 
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Table 3. Risk factors for HPV infection. 
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Younger age + NS NS +   NS NS  + 
Number of sexual partners + + + + + + + + + + 
Smoking  NS NS  + NS NS NS   
Alcohol and drug use +   + NS  NS +   
Oral contraceptive use  NS NS  + NS     
Condom use     NS   NS (-)*  
Tampon use     NS      
High frequency of vaginal sex + NS         
Anal sex +          
Douching       +    
STI diagnosis/history    + NS NS  NS   
Not married      NS  +  + 
Racial/minority group +   +      NS 
Age difference with partner   +    +    
Promiscuous partner +   + +    +  
Partner not in school +          
Partner age    +       
Partner race    + +      
* Protective factor; NS= Non Significant 
Adolescent sexual behavior 
A study carried out among US youth aged 14-22 years reported that grossly two thirds of both 
males and females were sexually experienced (28). UK data report a median age of 17 years at 
first intercourse both for males and females (29). In Switzerland, median age at first intercourse is 
18.5 years both for males and females, and the proportion of those having had sexual intercourse 
before age 15 is 6.8% for males and 3.4% for females (30). The rate of sexual activity 
(intercourse) among Swiss youth ranges from 13% of males and 7% of females at age 14 to 80% 
for both genders at age 20 (31;32) (Figure 1). 
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Figure 1. Sexually active adolescents aged 14-20 in Switzerland (31;32). 
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Overall, the percentage of sexually active Swiss aged 17-20 years has slightly increased from 
1992 to 2000 (Figure 2). 
Figure 2. Percentage of sexually active 17-20 year-olds. Switzerland: 1992-2000 (33). 
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Among American females aged 14-22 years, 72% had had only one sexual partner in the previous 
3 months, 8% had had 2 and 5% three or more. Among males, the rates were 50%, 12% and 14%, 
respectively, for the same age group. The lifetime number of sexual partners increased from 8% 
of females aged 14 reporting 6 or more partners to 31% of those aged 21. Among males, it varied 
between 14% and 45% for the same ages (28). Swiss data also indicate that one third of males 
aged 17-20 had had one partner in the previous year, 18% two, and 12% three or more. The 
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percentages for females in the same age group were, respectively, 48%, 10% and 5%. For males 
aged 21-30 years, 63% had had one partner, 10% two and 14% three or more. For females in this 
age group, the percentages were 85%, 5% and 4%. Finally, 85% of males aged 31-45 had had one 
partner, 5% two and 6% three, while for females the figures were 89%, 3% and 1% (33) (Figure 
3). Among sexually active adolescents aged 16-20 years in Switzerland, 47% of females and 33% 
males had ever had one partner, 39% of both genders had had 2 to 4, and 13% of females and 
28% of males had had five or more lifetime sexual partners (31). 
Figure 3. Number of sexual partners in the previous year. Switzerland, 2000 (33). 
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However, the trends in the number of sexual partners among Swiss youth aged 17-20 years show 
some changes between 1987 and 2000. Overall, the rates remain quite stable until 1994. At this 
point in time, while those having had 2 sexual partners remain stable slightly over 10%, those 
reporting 3 or more partners decline dramatically while those reporting only one partner raise 
importantly as do those who did not have a partner, although the later do it less markedly (33;34) 
(Figure 4). 
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Figure 4. Trends in the number of sexual partners among 17-20 year-olds, Switzerland: 1987-
2000 (33;34). 
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Among American youth, risk factors for having had two or more sexual partners in the previous 3 
months are alcohol and illicit drugs use and first intercourse at age 13 years or below for males 
and black race, alcohol use and first sexual intercourse before age 16 for females. Being married 
is a protective factor for both genders. For both genders, risk factors for having had 6 or more 
sexual partners in their life are age, black race, alcohol and illicit drug use and first sexual 
intercourse before age 16 (28). 
Vaccines 
HPV vaccines are characterized as therapeutic or prophylactic. Although the former ones are in 
very early stages of development and have shown limited success, the later have demonstrated 
high efficacy (1). A model based on UK data (35) estimated that for a vaccinated cohort of 12-
year-old girls there would be a reduction of 66% in the prevalence of high-grade precancerous 
lesions and a 76% reduction in cervical cancer deaths. A 95% reduction in the prevalence of 
HPV-16 and 18 associated lesions was also estimated. 
The duration of the vaccine’s protection is unclear (2) and results to date indicate a sustained 
efficacy up to 4.5 / 5 years (1;2). Consequently, the need for a booster is a research area of 
greatest importance (7). Moreover, if a booster is required, focusing vaccination programs on 12-
year-olds is more cost-effective than focusing on infants (36). 
As HPV acquisition occurs soon after sexual initiation, the vaccine would have greater 
effectiveness if administered to young adolescents before they have acquired vaccine HPV types 
(1), before the onset of sexual activity (37). 
It has also been debated whether males should also be vaccinated. Although some authors (38) 
report that vaccinating both men and women would result in a higher decrease in HPV 
prevalence, evidence to date indicate that vaccinating both genders had little benefit over 
vaccinating females only (39). Taira et al. (36) reported that including males in a vaccination 
 15
program would only slightly reduce infections and cancer cases with an unattractive cost-
effectiveness ratio. 
Questions posed 
Three questions arise regarding HPV vaccination: 
3. At what age should the vaccine be introduced in a routine schedule? 
4. Up to which age should the vaccine be recommended in catch-up form? 
5. Would boosters be necessary? 
To answer the first question, it is clear that the vaccine has to be implemented before the onset of 
sexual activity. The American Advisory Committee on Immunization Practices (ACIP) 
recommends to vaccinate females at age 11-12 years, and that the vaccination series can be 
started as young as 9 years of age (40). The American Cancer Society (ACS) (41) gives the same 
recommendations. This schedule is supported both by the American Academy of Pediatrics (42) 
and the Society for Adolescent Medicine (37). 
To tackle the second question, the ACIP also recommends catch-up vaccination for females aged 
13 to 26 years who have not received the vaccine or who have not completed the full vaccine 
series. Ideally, it should be administered before potential exposure to HPV through sexual 
contact. This schedule is also supported both by the American Academy of Pediatrics (42) and 
the Society for Adolescent Medicine (37). On the other hand, the ACS (41) recommends catch-up 
vaccination up to age 18 because there are insufficient data for or against vaccination among 
females aged 19-26 years. Vaccination beyond age 26 or for males is not recommended (41). In 
other countries such as the UK (43) and Canada (44) the recommendations are currently under 
review. 
The third question is probably the most difficult to answer, as we currently do not know the 
efficacy time frame of these vaccines. As stated previously, most authors report a sustained 
efficacy up to 4.5 / 5 years (1;2). 
Objective 
The objective of this report is to create a mathematical model using Swiss data to explore the 
theoretical HPV infection and vaccine coverage rates in the female Swiss population using 
different scenarios that take into account both the upper catch-up age limit and three different 
efficacy time-frames (5 years, 10 years, and lifelong). In all cases, the routine vaccination 
program would start at age 12. 
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DESCRIPTION OF THE HPV MODEL 
Introduction 
The tool developed by the GRSA for the modelling of HPV virus diffusion is based on the classic 
SIR model introduced first by Kermack & McKendrick (45) in 1927 and then broadly used in 
epidemiology (e.g. Anderson (46), Daley & Gani (47)). A similar, but less complete, HPV model 
has been proposed by Corley (48). Individuals in the model are classified as either Susceptible of 
being infected (state S), Infective (state I), or in Remission (state R). Two additional states, V for 
Vaccinated and VI for Vaccinated-Infective are also considered to take into account the effect of 
a vaccination program. State V groups individuals immune after having received a vaccine or a 
booster. State VI groups individuals having received a vaccine or a booster when already 
infected. For the purpose of clarity, the rare individuals belonging to this last state will be 
aggregated with Infective when presenting the results. The model considers both females and 
males, but given the goal of the present study, only results for females will be reported. 
The principle of the model is to follow a complete population made of individuals of ages 1 to 
100 of both genders. The model works in discrete time with a time unit equal to one year. At the 
beginning of the simulation (year 0), an initial population is generated. Proportions of individuals 
of ages 1, 2, …, 100 follow the mortality tables computed by Swiss Statistics for Switzerland. 
Each subsequent year of the simulation, the individuals of one particular age move to the next 
age. For instance, 20 years old individuals at time t become 21 years old individuals at time t+1. 
Individuals leave the model after they reach 100 years old, and new individuals of one year old 
enter into the model to replace them.  Each year of the simulation, individuals are classified into 
one of the 5 mutually-exclusive states (S, I, R, V, VI). Possible transitions from one state to 
another are described as difference equations. A set of parameters estimated from the literature 
ensures the best reproduction of transitions observed in the real world. By simulating the natural 
development of the population over a large number of years, the model is used to compute the 
yearly proportion of the total population belonging any time to each of the five states (S, I, R, V, 
VI). 
Individuals of each age are divided into several mutually exclusive sexual profiles corresponding 
to different groups of sexual activity. Each group is defined by the average number of different 
partnerships formed each year. A process of sexual mixing between these groups and between 
individuals of different ages is implemented to take into account the fact that many sexual 
partnerships involve individuals with different characteristics. Because data on sexual habits of 
Swiss people are scarce, we chose to divide the population of the model into 9 classes of age 1-
10, 11-14, 15-16, 17-20, 21-30, 31-45, 46-60, 61-80, 81-100. Sexual activity does not occur in 
the first and last classes. Parameters are fixed globally for all possible ages of a same class. For 
instance, individuals aged 21 to 30 years old share the same parameters.  
Different types of vaccination programs can be implemented to study their short- and long-term 
impact onto the population. Vaccination programs can include vaccination at a particular age, one 
or several boosters, and a catch-up procedure up to a given age, with or without booster. The 
impact of each vaccination scenario can be studied after a given number of years. It is also 
possible to obtain endemic long-term results. 
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Transitions between states  
Each year, individuals into the model move from one state to another following their sexual 
behaviour and the vaccination program if applicable. Figure 5 shows the possible transitions 
before vaccination occurs. Only states S, I, and R are then possible. Susceptible individuals can 
either stay Susceptible or become Infective. Infective individuals can either stay Infective or enter 
in Remission. Remission individuals can either stay in Remission or become Susceptible again. 
This last transition allows for the modelling of multiple successive HPV 16 or 18 infections by a 
same individual. 
Figure 5: Possible transitions before vaccination. 
 
Figure 6 shows the possible transitions at the exact age of the vaccination. Compared to the 
situation of Figure 5, states V and VI are also active. In most cases, individuals become 
Vaccinated either from the Susceptible or Remission states, but they can also come from the 
Infective state if they clear infection the same year they are vaccinated. On the other hand, they 
become Vaccinated-Infective (VI) if they are vaccinated when staying infected, or if they are 
Susceptible and get an infection the same year they are vaccinated.  
Figure 6: Possible transitions when vaccination occurs. 
 
After vaccination (Figure 7), individuals can stay in the Vaccinated and Vaccinated-Infective 
states, but they can also leave these states to become Susceptible, Infective, or enter in 
Remission. Vaccinated individuals become Susceptible again when the immunity provided by the 
vaccine vanishes, and they become Infective when they lose their immunity at the same time they 
get infected. Finally, they can also become Vaccinated-Infective if they get infected when 
keeping the immunity provided by the vaccine, but this very particular situation can occur only if 
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the vaccine doesn’t provide a 100% percent protection. Vaccinated-Infective individuals become 
simply Infective if the immunity provided by the vaccine vanishes, and they enter in Remission if 
they clear the infection at the same time. 
Figure 7: Possible transitions when vaccinated and non-vaccinated individuals coexist into the 
model. 
 
An even more complex situation occurs at the exact time a booster is administered (Figure 8). 
This complexity comes from different reasons: not all individuals will receive the booster; 
simultaneously to receiving the booster, an individual can also become infected, or clear an 
infection; a significant proportion of the population can be still protected by the vaccine. 
Figure 8: Possible transitions at the time of a booster. 
 
The years following a booster, transitions follow again the schema given on Figure 7. 
Parameters of the model 
Table 5 describes the parameters of the model and gives their values as estimated for Switzerland 
from the literature. As indicated in Table 5, the values of many parameters change in function of 
the vaccination scenario. Other parameters (duration, nbAge, Classes, p, Omega) have also been 
chosen in function of the objective of the study and of the availability of Swiss data. The 
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parameter popAge is used as an internal reference for the model. Its value is arbitrary chosen and 
does not influence the results of the model.  
There are 20 profiles of sexual activity, each of them grouping exactly 5% of the total population 
of a particular age. Each profile corresponds to a different group of population. Such a large 
number of profiles is not mandatory, but given the Swiss data available for parameter estimation, 
it was the best choice. For each profile and each class of age, the average number of sexual 
partnerships formed by year is freely chosen (parameter C), but these values have to be identical 
for both genders, so a weighted average is computed from each gender data. If required, several 
profiles can be assigned the same characteristics. 
The following matrix gives the value of C (average number of sexual partnerships per year) for 
each age class and each sexual activity profile. The first and last age classes are non-sexually 
active classes. These classes group people without any sexual activity involving partners, so they 
take only zeros values in the matrix. 
Table 4: C matrix giving the average number of sexual partnerships formed each year, by age 
class and profile of sexual activity. 
 Profiles of sexual activity 
Age class 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1-10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
11-14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 
15-16 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 2 2 5 7 9 
17-20 0 0 0 0 0 0 1 1 1 1 1 1 1 2 2 2 2 3 5 7 
21-30 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 3 3 3 
31-45 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 3 
46-60 0 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 2 3 
61-80 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 1 2 3 
81-100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
The parameter of sexual mixing (epsilon) takes a value of 0.8 reflecting the fact that with no less 
than 20 different profiles of sexual activity, it is likely that the majority of the sexual partnerships 
are formed with individuals belonging to another profile. 
The Phivacc, PhiBoost, and PhiCatchup parameters have been fixed to 85% (female) and 0% 
(male). The latter case is a consequence of the choice of not exploring male vaccination. Since no 
data exist at the time for HPV, the vaccination rate for females has been derived from the one for 
Hepatitis B. In Switzerland this rate is low (41%) (49) since vaccination is not mandatory in all 
cantons, so we used data from other European countries (Italy: 92%, Germany: 84%, Austria: 
92%) (50). 
The number of yeard separating vaccination or catch-up from a booster (parameters AgeBoost 
and DelBoostCatchup) is equal to the assumed length of the total immunity provided by the 
vaccine. This strategy insures that no sudden diminution in the proportion of vaccinated females 
will occur before the end of the period covered by the chosen vaccination program.
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Table 5: Parameters of the HPV model. We describe here all parameters of the simulation model, and we provide their values as estimated 
for Switzerland from the literature. When needed, the main source used to estimate the parameter is provided in the last column, but in many 
cases the estimation provided here is a combination of different sources. “Specific” indicates that the value has been chosen specifically in 
regard of the objective of the present study.  
Parameter Estimation Description Main source for 
estimation 
General 
duration 100 Length of the simulation in years.  Specific. 
nbAge 9 Number of age classes. Specific. 
Classe 1-10, 11-14, 15-16, 17-20, 
21-30, 31-45, 46-60, 61-80, 81-100 
Initial and final age of each class. Specific. 
p 20 Number of sexual activity profiles. Specific. 
popAge 1000 Total number of one year old individuals (female 
and male) into the model. 
Specific. 
Surv Available upon request. Survival probability for individual of each age, by 
sex. 
Swiss Statistics 
Infect Available upon request. Endemic 
values computed from the reference 
scenario without vaccination 
program. 
Initial proportion of the population being infected 
by the HPV virus, by age, sex and sexual activity 
profile. 
Specific. 
Vaccination 
ageVacc 12 Age of the vaccination. Taira et al. (36) 
PhiVacc female : 85%, male : 0% Percentage of individuals being vaccinated at age 
ageVacc, by sex. 
Specific. 
AgeBoost dVacc years after vaccination or last 
booster  
Age of the booster (if applicable). Multiple 
boosters are possible. 
Specific. 
PhiBoost female : 85%, male : 0% Percentage of individuals receiving a booster, by 
sex. 
Specific. 
dVacc 5 or 10 (depending on the scenario) Length in years of the total immunity provided by 
the vaccine. 
Dunne & Markowitz 
(1); Clifford et al. (24) 
dBoost 5 or 10 (depending on the scenario) Length in years of the total immunity provided by 
the booster. 
Dunne & Markowitz 
(1); Clifford et al. (24) 
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catchup 0 or 1 (depending on the scenario) Catch-up procedure (0 : no, 1 : yes). Specific. 
ageSupCatchup 18, 20, 22 or 25 (depending on the 
scenario) 
Maximal age to receive the catch-up. ACIP (40); ACS (41) 
PhiCatchup female : 85%, male : 0% Percentage of individuals receiving the catch-up, 
by sex. 
Specific. 
DelBoostCatchup dBoost years after catch-up or last 
booster (depending on the scenario) 
Delay in years before receiving a booster post-
catch-up. Multiple boosters are possible. 
Specific. 
maxAgeBoostCatchup 25 Maximal age to receive a booster post-catch-up. ACS (41) 
Sigma 0% during the first dVacc years 
following vaccination, then 10%  
Proportion of vaccinated individuals losing their 
immunity by years during the period of total 
immunity, and then after this period. 
Koutsky & Harper (51) 
r 1 Relative risk of virus transmission between VI and 
I individuals. 
Hughes, Garnett & 
Koutsky (38) 
Sexuality 
C See text. 
 
Average number of sexual partnerships formed by 
year, for each sexual activity profile and each age 
class. 
IUMSP/UEPP (33), 
SMASH02 (31) 
Omega 5% per profile Proportion of the total population belonging to 
each profile of sexual activity. 
Specific. 
epsilon 0.8 Proportion of the population forming sexual 
partnerships with individuals belonging to other 
profiles of sexual activity. 
Specific. 
Psi female : 0%, male : 0% Relative risk of infection between vaccinated and 
non-vaccinated individuals, by sex. 
Koutsky & Harper (51) 
Beta female to male : 75% 
male to female : 75% 
Transmission rate of the virus from one sex to 
another. 
Hughes, Garnett & 
Koutsky (38) 
States transitions 
gamma 70% Proportion of infective individuals entering in 
remission each year. 
CDC (2) 
alpha 1 Relative rate of remission entering between states 
VI and V. 
Hughes, Garnett & 
Koutsky (38) 
delta 0.5 Proportion of remission individuals becoming 
susceptible again each year. 
Specific. 
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Model 
The model works in discrete time, each period being one year. The transitions from any state 
of the model (S, I, R, V, VI) to any other state are modelled through a set of difference 
equations. Each year of the simulation, the proportion of individuals of sexual activity profile 
p and age a going from state s to state u is computed.  
The core of any model for sexually transmitted viruses is a complex process of sexual mixing 
between individuals. This process manages all sexual contacts made between individuals, 
hence all possibilities of virus transmission. The process of sexual mixing used in this model 
is derived from the one proposed by Garnett (52). Each year of the simulation, a matrix called 
Rho indicating the proportion of sexual contacts occurring between each couple of sexual 
activity profiles is computed for each age. Then, a second matrix called Lambda giving the 
force of infection of each individual is computed from Rho and from the average number of 
partnerships C.  On the contrary of the solution adopted in several previous models, the 
process implemented here takes explicitly into account the fact that partnerships between 
individuals of different ages are very frequent.  
At the beginning of the simulation, an initial population is created. This population mimics 
the Swiss population by the use of the real Swiss mortality table and by an HPV infection rate 
by age corresponding to the endemic situation predicted by the model. Then, each subsequent 
year of the simulation consists in the following steps: 
i. The sexual mixing between the different groups of population is computed from the 
final situation of the previous year. 
ii. A new repartition of the population between the 5 states is computed using the set of 
difference equations and the final situation of the previous year. 
iii. The results are adjusted according to the Swiss mortality table to respect the real 
repartition between the different ages. 
Intermediary results are available after any number of simulation years. If a vaccination 
program is implemented at the beginning of the simulation, the impact of this program can be 
analyzed after any given number of years. The equilibrium of the model provides the endemic 
repartition of the population between the 5 states.  
The model has been developed using Matlab 7. Stata 9 has been used for statistical 
computations. 
 23
RESULTS 
Current scenario: no vaccination 
Using current Swiss data in the model simulation, HPV infection rate would peak at ages 18 
(15.5%) and 22 years (15.7%) to slowly decline afterwards to 8.2% at age 60. 
The infection rate for HPV types 16 and 18 peaks at age 18 (9.4%), is reduced in half at the 
end of the third decade (4.7% at age 30) and remains around 2% from age 40 onwards (Figure 
9 and Table 6). 
Figure 9. Estimated HPV infection rate by age: global and for types 16 and 18, Switzerland. 
Table 6. Estimated HPV infection rate by age: global and for types 16 and 18, Switzerland (in 
percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
All HPV types 2.1 2.0 14.0 15.5 14.1 15.7 14.3 13.1 10.3 10.1 7.9 8.2 
HPV types 16-18 0.9 1.1 9.0 9.4 8.7 8.1 6.6 4.7 2.5 1.9 1.6 2.1 
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Estimated situation in 15 years: infection rate 
Scenarios 1 to 5 define what would be the theoretical situation fifteen years after the initiation 
of the vaccination program depending on whether or not there is a catch-up and, if there were 
one, up to what age. 
The 15-year horizon has been chosen because at that moment the first vaccinated cohort at 
age 12 will reach age 27, beyond the maximum age described currently in the literature as the 
maximum catch-up age. 
For each scenario, 5 possibilities regarding the vaccine have been tested: 
1. Vaccine with 5-year efficacy, no booster. 
2. Vaccine with 5-year efficacy with two boosters at ages 17 and 22. 
3. Vaccine with 10-year efficacy, no booster. 
4. Vaccine with 10-year efficacy with a booster 10 years later (age 22). 
5. Vaccine with lifelong efficacy. 
We have avoided to introduce a sixth possibility (vaccines with 5-year efficacy plus one 
booster 5 years later) because it is barely the same situation than for a 10-year efficacy 
vaccine. 
For all scenarios some assumptions have been made: 
• Only girls would be vaccinated. 
• Universal vaccination program. 
• An expected vaccination coverage rate of 85%. 
In all the scenarios including a catch-up, it has been assumed that it would be done in the first 
year of the implementation of the vaccination program. Although longer catch-up periods 
(three years, for example) could have been assumed, they would have little influence on the 
results. 
Finally, the infection rates described below include only females and are only referred to HPV 
types 16 and 18. 
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Scenario 1: No catch-up, estimated situation in 15 years. 
Using a 5-year efficacy vaccine the infection rate would remain below 1% up to age 18, 
below 2% up to age 22 and below 4% up to age 30. By adding 2 boosters, the rate would 
remain below 1% up to age 25 and under 4% up to age 30. A 10-year efficacy vaccine would 
maintain the infection rate under 1% up to age 22, slightly over 1% at age 25 and below 4% at 
age 30. The addition of a booster would imply that the rate would remain below 1% up to age 
25 and under 4% up to age 30. A lifelong efficacy vaccine would follow a very similar curve. 
In all cases, from age 35 onwards, the rates are as if no vaccination was administered (Figure 
10 and Table 7). 
Figure 10. Estimated HPV infection rate by age, Switzerland. Scenario at 15 years without 
catch-up. 
Table 7. Infection rate by age and type of vaccination. Scenario at 15 years without catch-up 
(in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No vaccine 0.88 1.14 9.03 9.42 8.73 8.1 6.59 4.69 2.52 1.91 1.57 2.14 
Efficacy 5 y/No booster 0.19 0.06 0.53 0.63 1.32 1.81 2.49 3.92 2.5 2.12 1.83 2.32 
Efficacy 5 y/2 boosters 0.15 0.05 0.42 0.54 0.55 0.53 0.58 3.7 2.47 2.12 1.83 2.32 
Efficacy 10 y/No booster 0.15 0.05 0.42 0.51 0.55 0.54 1.13 3.71 2.47 2.12 1.83 2.32 
Efficacy 10 y/Booster 10 y 0.15 0.05 0.42 0.51 0.55 0.54 0.58 3.7 2.47 2.12 1.83 2.32 
Efficacy lifelong 0.15 0.05 0.42 0.51 0.55 0.54 0.62 3.71 2.47 2.12 1.83 2.32 
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Scenario 2: Catch-up to age 18, estimated situation in 15 years. 
With a catch-up to age 18, a 5-year efficacy vaccine would maintain the infection rate under 
1% up to age 20 and below 2.5% up to age 35. By adding 2 boosters, the rate would stay 
below 1% up to age 30 and below 2% up to age 35. A 10 year efficacy vaccine would keep 
the rate below 1% up to age 25 and below 2% up to age 35. By adding a booster 10 years later 
or using a lifelong efficacy vaccine, the scenario would be very close to the 5-years+boosters 
case. In all cases, the infection rate would be similar to non-vaccination from age 40 onwards 
(Figure 11 and Table 8). 
Figure 11. Estimated HPV infection rate by age, Switzerland. Scenario at 15 years with catch-
up to age 18. 
Table 8. Infection rate by age and type of vaccination. Scenario at 15 years with catch-up to 
age 18 (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No vaccine 0.88 1.14 9.03 9.42 8.73 8.1 6.59 4.69 2.52 1.91 1.57 2.14 
Efficacy 5 y/No booster 0.13 0.05 0.39 0.47 0.96 1.29 1.76 2.25 2.13 2.02 1.83 2.32 
Efficacy 5 y/2 boosters 0.08 0.03 0.22 0.27 0.26 0.22 0.22 0.82 1.78 1.95 1.83 2.32 
Efficacy 10 y/No booster 0.09 0.03 0.25 0.3 0.31 0.28 0.57 1.35 1.93 1.98 1.83 2.32 
Efficacy 10 y/Booster 10 y 0.09 0.03 0.25 0.29 0.29 0.25 0.26 0.84 1.89 1.97 1.83 2.32 
Efficacy lifelong 0.09 0.03 0.25 0.29 0.29 0.26 0.29 0.69 1.88 1.97 1.83 2.32 
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Scenario 3: Catch-up to age 20, estimated situation in 15 years. 
A catch-up to age 20 would maintain the infection rate below 1% up to age 20 and to a 
maximum of 2% up to age 35 with a 5-yer efficacy vaccine without booster. By adding 2 
boosters or using a 10-year efficacy vaccine with booster or a lifelong efficacy vaccine, the 
rate would remain under 1% up to age 30 and below 2% up to age 35. I f no booster was 
administered after the 10-year efficacy vaccine, the rate would be kept under 1% up to age 25 
and under 2% up to age 35 (Figure 12 and Table 9). 
Figure 12. Estimated HPV infection rate by age, Switzerland. Scenario at 15 years with catch-
up to age 20. 
Table 9. Infection rate by age and type of vaccination. Scenario at 15 years with catch-up to 
age 20 (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No vaccine 0.88 1.14 9.03 9.42 8.73 8.1 6.59 4.69 2.52 1.91 1.57 2.14 
Efficacy 5 y/No booster 0.13 0.04 0.37 0.44 0.89 1.18 1.59 2 1.93 1.94 1.82 2.32 
Efficacy 5 y/2 boosters 0.07 0.03 0.2 0.24 0.22 0.18 0.15 0.56 1.45 1.81 1.82 2.32 
Efficacy 10 y/No booster 0.08 0.03 0.23 0.27 0.28 0.24 0.46 1.08 1.66 1.87 1.82 2.32 
Efficacy 10 y/Booster 10 y 0.08 0.03 0.23 0.26 0.26 0.22 0.21 0.66 1.62 1.87 1.82 2.32 
Efficacy lifelong 0.08 0.03 0.23 0.26 0.26 0.22 0.23 0.54 1.6 1.86 1.82 2.32 
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Scenario 4: Catch-up to age 22, estimated situation in 15 years. 
A catch-up to age 22 would result in an infection rate below 1% up to age 20 and below 2% 
up to age 35 with a 5-year efficacy vaccine. In all other cases, the rate would be maintained 
below 1% up to age 35 (Figure 13 and Table 10). 
Figure 13. Estimated HPV infection rate by age, Switzerland. Scenario at 15 years with catch-
up to age 22. 
Table 10. Infection rate by age and type of vaccination. Scenario at 15 years with catch-up to 
age 22 (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No vaccine 0.88 1.14 9.03 9.42 8.73 8.1 6.59 4.69 2.52 1.91 1.57 2.14 
Efficacy 5 y/No booster 0.12 0.04 0.35 0.42 0.84 1.09 1.44 1.75 1.29 1.82 1.82 2.32 
Efficacy 5 y/2 boosters 0.07 0.03 0.19 0.22 0.21 0.16 0.13 0.42 0.69 1.68 1.82 2.32 
Efficacy 10 y/No booster 0.08 0.03 0.22 0.26 0.26 0.22 0.38 0.84 0.79 1.72 1.82 2.32 
Efficacy 10 y/Booster 10 y 0.08 0.03 0.21 0.25 0.24 0.2 0.17 0.51 0.5 1.71 1.82 2.32 
Efficacy lifelong 0.08 0.03 0.21 0.25 0.24 0.2 0.19 0.41 0.4 1.7 1.82 2.32 
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Scenario 5: Catch-up to age 25, estimated situation in 15 years. 
A 5-year efficacy vaccine without booster would result in an infection rate below 1% up to 
age 20 and below 2% up to age 40. For all other cases, the rate would be maintained under 
1.5% up to age 40 (Figure 14 and Table 11). 
Figure 14. Estimated HPV infection rate by age, Switzerland. Scenario at 15 years with catch-
up to age 25. 
Table 11. Infection rate by age and type of vaccination. Scenario at 15 years with catch-up to 
age 25 (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No vaccine 0.88 1.14 9.03 9.42 8.73 8.1 6.59 4.69 2.52 1.91 1.57 2.14 
Efficacy 5 y/No booster 0.11 0.04 0.33 0.39 0.78 1 1.26 1.44 1.04 1.6 1.8 2.32 
Efficacy 5 y/2 boosters 0.07 0.02 0.18 0.21 0.19 0.15 0.1 0.28 0.49 1.42 1.8 2.32 
Efficacy 10 y/No booster 0.08 0.03 0.21 0.24 0.24 0.2 0.31 0.59 0.56 1.43 1.8 2.32 
Efficacy 10 y/Booster 10 y 0.08 0.03 0.2 0.23 0.22 0.18 0.14 0.35 0.35 1.41 1.79 2.32 
Efficacy lifelong 0.08 0.03 0.2 0.23 0.23 0.18 0.16 0.28 0.27 1.39 1.79 2.32 
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Estimated situation in 30 years: infection rate 
Scenarios 6 to 10 define what would be the theoretical situation thirty years after the initiation 
of the vaccination program depending on whether or not there is a catch-up and, if there were 
one, up to what age. 
The 30-year horizon has been chosen because from that moment onwards the model remains 
stable. 
As for the 15 years situation, for each scenario 5 possibilities regarding the vaccine have been 
tested: 
1. Vaccine with 5-year efficacy, no booster. 
2. Vaccine with 5-year efficacy with two boosters at ages 17 and 22. 
3. Vaccine with 10-year efficacy, no booster. 
4. Vaccine with 10-year efficacy with a booster 10 years later (age 22). 
5. Vaccine with lifelong efficacy. 
We have avoided to introduce a sixth possibility (vaccines with 5-year efficacy plus one 
booster 5 years later) because it is barely the same situation than for a 10-year efficacy 
vaccine. 
Similarly, the same assumptions as above have been made for all scenarios: 
• Only girls would be vaccinated. 
• Universal vaccination program. 
• An expected vaccination coverage rate of 85%. 
In all the scenarios including a catch-up, it has been assumed that it would be done in the first 
year of the implementation of the vaccination program. Although longer catch-up periods 
(three years, for example) could have been assumed, they would have little influence on the 
results. 
As previously mentioned, the infection rates described below include only females and are 
only referred to HPV types 16 and 18. 
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Scenario 6: No catch-up, estimated situation in 30 years. 
A 5-year vaccine with no booster would maintain the infection rate below 1% up to age 25 
and below 1.3% up to age 40. All other options would result in a rate below 1% up to age 40. 
In all cases, the rates would be as if not vaccinated afterwards, For a lifelong efficacy vaccine, 
the rates would remain under 0.2% up to age 40 (Figure 15 and Table 12). 
Figure 15. Estimated HPV infection rate by age, Switzerland. Scenario at 30 years without 
catch-up. 
Table 12. Infection rate by age and type of vaccination. Scenario at 30 years without catch-up 
(in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No vaccine 0.88 1.14 9.03 9.42 8.73 8.1 6.59 4.69 2.52 1.91 1.57 2.14 
Efficacy 5 y/No booster 0.07 0.02 0.21 0.26 0.54 0.71 0.97 1.26 1.07 1.25 1.54 2.15 
Efficacy 5 y/2 boosters 0.02 0.01 0.05 0.06 0.05 0.04 0.03 0.08 0.28 0.72 1.5 2.15 
Efficacy 10 y/No booster 0.02 0.01 0.06 0.07 0.08 0.07 0.13 0.39 0.58 0.97 1.52 2.15 
Efficacy 10 y/Booster 10 y 0.02 0.01 0.05 0.05 0.05 0.04 0.02 0.02 0.1 0.49 1.49 2.15 
Efficacy lifelong 0.02 0.01 0.05 0.05 0.05 0.04 0.02 0.02 0.05 0.15 1.49 2.15 
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Scenario 7: Catch-up to age 18, estimated situation in 30 years. 
With a catch-up to age 18, and with the exception of a 5-year vaccine with no booster at age 
40 (1.08%), the rate would always be maintained below 1% up to age 40  for any other type of 
vaccination (Figure 16 and Table 13). 
Figure 16. Estimated HPV infection rate by age, Switzerland. Scenario at 30 years with catch-
up to age 18. 
Table 13. Infection rate by age and type of vaccination. Scenario at 30 years with catch-up to 
age 18 (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No vaccine 0.88 1.14 9.03 9.42 8.73 8.1 6.59 4.69 2.52 1.91 1.57 2.14 
Efficacy 5 y/No booster 0.06 0.02 0.18 0.23 0.46 0.61 0.83 1.07 0.9 1.08 1.48 2.15 
Efficacy 5 y/2 boosters 0.01 0 0.03 0.03 0.03 0.02 0.02 0.05 0.18 0.52 1.4 2.14 
Efficacy 10 y/No booster 0.01 0 0.04 0.05 0.05 0.04 0.08 0.25 0.41 0.75 1.43 2.14 
Efficacy 10 y/Booster 10 y 0.01 0 0.03 0.03 0.03 0.02 0.01 0.01 0.04 0.28 1.35 2.14 
Efficacy lifelong 0.01 0 0.03 0.03 0.03 0.02 0.01 0.01 0.01 0.06 1.31 2.14 
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Scenario 8: Catch-up to age 20, estimated situation in 30 years. 
With the exceptions of age 30 (1.02%) and 40 (1.03%), a 5-year efficacy vaccine would result 
in a rate under 1%, like in all the other options up to age 40 (Figure 17 and Table 14). 
Figure 17. Estimated HPV infection rate by age, Switzerland. Scenario at 30 years with catch-
up to age 20. 
Table 14. Infection rate by age and type of vaccination. Scenario at 30 years with catch-up to 
age 20 (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No vaccine 0.88 1.14 9.03 9.42 8.73 8.1 6.59 4.69 2.52 1.91 1.57 2.14 
Efficacy 5 y/No booster 0.06 0.02 0.18 0.22 0.45 0.59 0.8 1.02 0.86 1.03 1.45 2.14 
Efficacy 5 y/2 boosters 0.01 0 0.02 0.03 0.03 0.02 0.01 0.04 0.15 0.46 1.34 2.13 
Efficacy 10 y/No booster 0.01 0 0.04 0.04 0.04 0.04 0.07 0.22 0.36 0.69 1.39 2.14 
Efficacy 10 y/Booster 10 y 0.01 0 0.03 0.03 0.03 0.02 0.01 0.01 0.04 0.23 1.27 2.13 
Efficacy lifelong 0.01 0 0.03 0.03 0.03 0.02 0.01 0.01 0.01 0.05 1.19 2.12 
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Scenario 9: Catch-up to age 22, estimated situation in 30 years. 
In all cases, an infection rate below 1% up to age 40 would be expected. This low rate would 
even be maintained up to age 50 in the case of a 10-year efficacy vaccine with a booster 10 
years later or a lifelong efficacy vaccine. In the other cases, the rate would be below 1.4% at 
age 50 (Figure 18 and Table 15). 
Figure 18. Estimated HPV infection rate by age, Switzerland. Scenario at 30 years with catch-
up to age 22. 
Table 15. Infection rate by age and type of vaccination. Scenario at 30 years with catch-up to 
age 22 (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No vaccine 0.88 1.14 9.03 9.42 8.73 8.1 6.59 4.69 2.52 1.91 1.57 2.14 
Efficacy 5 y/No booster 0.05 0.02 0.17 0.21 0.43 0.56 0.76 0.97 0.82 0.97 1.34 2.14 
Efficacy 5 y/2 boosters 0.01 0 0.02 0.03 0.02 0.02 0.01 0.03 0.14 0.41 1.17 2.12 
Efficacy 10 y/No booster 0.01 0 0.03 0.04 0.04 0.03 0.06 0.2 0.32 0.62 1.22 2.13 
Efficacy 10 y/Booster 10 y 0.01 0 0.02 0.03 0.03 0.02 0.01 0.01 0.03 0.19 0.88 2.11 
Efficacy lifelong 0.01 0 0.02 0.03 0.03 0.02 0.01 0 0.01 0.03 0.34 2.1 
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Scenario 10: Catch-up to age 25, estimated situation in 30 years. 
A lifelong efficacy vaccine or a 10-year vaccine with a booster would maintain the infection 
rate below 1% up to age 50. In all the other options, the rate would be under 1% up to age 40 
and slightly over 1% at age 50 (Figure 19 and Table 16). 
Figure 19. Estimated HPV infection rate by age, Switzerland. Scenario at 30 years with catch-
up to age 25. 
Table 16. Infection rate by age and type of vaccination. Scenario at 30 years with catch-up to 
age 25 (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No vaccine 0.88 1.14 9.03 9.42 8.73 8.1 6.59 4.69 2.52 1.91 1.57 2.14 
Efficacy 5 y/No booster 0.05 0.02 0.16 0.2 0.41 0.53 0.72 0.91 0.75 0.9 1.27 2.12 
Efficacy 5 y/2 boosters 0.01 0 0.02 0.02 0.02 0.02 0.01 0.03 0.11 0.35 1.08 2.09 
Efficacy 10 y/No booster 0.01 0 0.03 0.04 0.04 0.03 0.05 0.16 0.26 0.53 1.11 2.10 
Efficacy 10 y/Booster 10 y 0.01 0 0.02 0.03 0.02 0.02 0.01 0.01 0.02 0.13 0.71 2.05 
Efficacy lifelong 0.01 0 0.02 0.03 0.02 0.02 0.01 0 0 0.02 0.24 2.02 
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Estimated situation in 15 years: vaccination coverage 
Scenarios 11 to 15 define what would be the theoretical situation fifteen years after the 
initiation of the vaccination program from the point of view of the vaccination coverage. 
Each scenario represents a different vaccination option and is described for the different 
catch-up possibilities (none and up to 18, 20, 22 and 25 years). 
In all the possibilities including a catch-up, it has been assumed that it would be done in the 
first year of the implementation of the vaccination program. Although longer catch-up periods 
(three years, for example) could have been assumed, they would have little influence on the 
results. 
The same assumptions that have been used all through the report have also been made for all 
scenarios: 
• Only girls would be vaccinated. 
• Universal vaccination program. 
• An expected vaccination coverage rate of 85%. 
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Scenario 11: 5-year efficacy vaccine without booster. Estimated situation in 15 
years. 
In the case of a 5-year efficacy vaccine without booster, whatever there is a catch-up or not, 
the maximum vaccination coverage (85%) would be maintained up to age 17. Afterwards it 
would slowly diminish to reach 50% of the females aged 22. Without a catch-up, there would 
be no coverage at all for those aged 30 years or older. With a catch-up to ages 18 or 20, no 
coverage would be observed from age 35 onwards, and with a catch-up to ages 22 or 25, the 
vaccination coverage would be inexistent for those aged 40 or more (Figure 20 and Table 17). 
Figure 20. Estimated vaccination coverage by age, Switzerland. Scenario at 15 years for a 5-
year efficacy vaccine without booster. 
 
Table 17. Vaccination coverage using a 5-year efficacy vaccine without booster by age. 
Scenario at 15 years (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No catch-up 84.8 84.8 84.7 76.2 61.6 49.8 36.1 0.0 0.0 0.0 0.0 0.0 
Catch-up to age 18 84.9 84.9 84.8 76.3 61.8 49.9 36.1 23.3 0.0 0.0 0.0 0.0 
Catch-up to age 20 84.9 84.9 84.8 76.3 61.8 49.9 36.1 23.3 0.0 0.0 0.0 0.0 
Catch-up to age 22 84.9 84.9 84.9 76.3 61.8 50.0 36.1 23.3 22.7 0.0 0.0 0.0 
Catch-up to age 25 84.9 84.9 84.9 76.3 61.8 50.0 36.1 23.3 22.7 0.0 0.0 0.0 
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Scenario 12: 5-year efficacy vaccine with 2 boosters. Estimated situation in 15 
years. 
A 5-year vaccine with 2 boosters (at ages 17 and 22) would maintain the maximum expected 
vaccination coverage up to age 25 in all cases. Without catch-up, no coverage would be 
observed at age 30 and up. Any catch-up would still give a 50% coverage of those aged 30. 
Only a catch-up at ages 22 or 25 would allow some coverage (38.4%) at age 35 (Figure 21 
and Table 18). 
Figure 21. Estimated vaccination coverage by age, Switzerland. Scenario at 15 years for a 5-
year efficacy vaccine with 2 boosters. 
 
Table 18. Vaccination coverage using a 5-year efficacy vaccine with 2 boosters by age. 
Scenario at 15 years (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No catch-up 84.9 84.8 84.7 84.5 84.4 84.6 84.3 0.0 0.0 0.0 0.0 0.0 
Catch-up to age 18 84.9 84.9 84.9 84.8 84.7 84.8 84.7 49.1 0.0 0.0 0.0 0.0 
Catch-up to age 20 84.9 84.9 84.9 84.8 84.7 84.8 84.7 49.2 0.0 0.0 0.0 0.0 
Catch-up to age 22 84.9 84.9 84.9 84.8 84.7 84.9 84.8 49.3 38.4 0.0 0.0 0.0 
Catch-up to age 25 84.9 84.9 84.9 84.8 84.7 84.9 84.8 49.4 38.4 0.0 0.0 0.0 
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Scenario 13: 10-year efficacy vaccine without booster. Estimated situation in 15 
years. 
A vaccine with an efficacy of 10 years not including a booster would maintain the maximum 
coverage up to age 22 years no matter whether a catch-up or not was incorporated. With a 
catch-up at age 18 or 20, a 39% coverage would still be observed at age 30, and with a catch-
up up to age 22 or 25, 38% of women aged 35 would still be protected (Figure 22 and Table 
19). 
Figure 22. Estimated vaccination coverage by age, Switzerland. Scenario at 15 years for a 10-
year efficacy vaccine without booster. 
 
Table 19. Vaccination coverage using a 10-year efficacy vaccine without booster by age. 
Scenario at 15 years (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No catch-up 84.9 84.8 84.7 84.6 84.5 84.3 61.1 0.0 0.0 0.0 0.0 0.0 
Catch-up to age 18 84.9 84.9 84.9 84.8 84.7 84.6 61.1 39.4 0.0 0.0 0.0 0.0 
Catch-up to age 20 84.9 84.9 84.9 84.8 84.7 84.6 61.1 39.4 0.0 0.0 0.0 0.0 
Catch-up to age 22 84.9 84.9 84.9 84.8 84.7 84.6 61.1 39.4 38.4 0.0 0.0 0.0 
Catch-up to age 25 84.9 84.9 84.9 84.8 84.7 84.6 61.1 39.4 38.4 0.0 0.0 0.0 
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Scenario 14: 10-year efficacy vaccine with booster. Estimated situation in 15 years. 
By adding a booster 10 years later to a 10-year efficacy vaccine, a vaccination coverage of 
85% would be maintained up to age 25. With any catch-up, two thirds of women aged 30 
would still be covered, and with a catch-up to ages 22 or 25, 65% of those aged 35 would still 
be under the influence of the vaccine (Figure 23 and Table 20). 
Figure 23. Estimated vaccination coverage by age, Switzerland. Scenario at 15 years for a 10-
year efficacy vaccine with booster. 
Table 20. Vaccination coverage using a 10-year efficacy vaccine with booster by age. 
Scenario at 15 years (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No catch-up 84.9 84.8 84.7 84.6 84.5 84.5 84.3 0.0 0.0 0.0 0.0 0.0 
Catch-up to age 18 84.9 84.9 84.9 84.8 84.7 84.8 84.6 66.7 0.0 0.0 0.0 0.0 
Catch-up to age 20 84.9 84.9 84.9 84.8 84.7 84.8 84.6 66.7 0.0 0.0 0.0 0.0 
Catch-up to age 22 84.9 84.9 84.9 84.8 84.7 84.8 84.7 66.7 65.0 0.0 0.0 0.0 
Catch-up to age 25 84.9 84.9 84.9 84.8 84.7 84.8 84.7 66.7 65.0 0.0 0.0 0.0 
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Scenario 15: lifelong efficacy vaccine. Estimated situation in 15 years. 
In the case of a vaccine with lifelong efficacy, 15 years after the implementation of the 
program the maximum coverage would be accomplished up to age 25. With any catch-up, at 
age 30 still three out of every four women would be covered. A catch-up to age 22 or 25 
would still maintain a 72% coverage at age 35 (Figure 24 and Table 21). 
Figure 24. Estimated vaccination coverage by age, Switzerland. Scenario at 15 years for a 
lifelong efficacy vaccine. 
 
Table 21. Vaccination coverage using a lifelong efficacy vaccine by age. Scenario at 15 years 
(in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No catch-up 84.9 84.8 84.7 84.6 84.5 84.3 83.8 0.0 0.0 0.0 0.0 0.0 
Catch-up to age 18 84.9 84.9 84.9 84.8 84.7 84.6 83.8 74.2 0.0 0.0 0.0 0.0 
Catch-up to age 20 84.9 84.9 84.9 84.8 84.7 84.6 83.8 74.2 0.0 0.0 0.0 0.0 
Catch-up to age 22 84.9 84.9 84.9 84.8 84.7 84.6 83.8 74.2 72.2 0.0 0.0 0.0 
Catch-up to age 25 84.9 84.9 84.9 84.8 84.7 84.6 83.8 74.2 72.2 0.0 0.0 0.0 
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Estimated situation in 30 years: vaccination coverage 
Scenarios 16 to 20 define what would be the theoretical situation thirty years after the 
initiation of the vaccination program from the point of view of the vaccination coverage. 
Each scenario represents a different vaccination option and is described for the different 
catch-up possibilities (none and up to 18, 20, 22 and 25 years). 
In all the possibilities including a catch-up, it has been assumed that it would be done in the 
first year of the implementation of the vaccination program. Although longer catch-up periods 
(three years, for example) could have been assumed, they would have little influence on the 
results. 
The same assumptions that have been used all through the report have also been made for all 
scenarios: 
• Only girls would be vaccinated. 
• Universal vaccination program. 
• An expected vaccination coverage rate of 85%. 
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Scenario 16: 5-year efficacy vaccine without booster. Estimated situation in 30 
years. 
In a 30 year perspective, a vaccine with an efficacy of 5 years without booster would maintain 
the maximum expected coverage of 85% up to age 17. By age 22, a 50% coverage would still 
be sustained. Only 7% of those aged 40 would still be covered whatever the case. With a 
catch-up to age 22 or 25, a 5% coverage could be observed at age 50 (Figure 25 and Table 
22). 
Figure 25. Estimated vaccination coverage by age, Switzerland. Scenario at 30 years for a 5-
year efficacy vaccine without booster. 
Table 22. Vaccination coverage using a 5-year efficacy vaccine without booster by age. 
Scenario at 30 years (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No catch-up 84.9 84.9 84.9 76.4 61.9 50.1 36.5 21.5 12.7 7.4 0.0 0.0 
Catch-up to age 18 85.0 84.9 84.9 76.4 61.9 50.1 36.5 21.6 12.7 7.4 0.0 0.0 
Catch-up to age 20 85.0 84.9 84.9 76.4 61.9 50.1 36.6 21.6 12.7 7.4 0.0 0.0 
Catch-up to age 22 85.0 85.0 84.9 76.4 61.9 50.1 36.6 21.6 12.7 7.4 4.7 0.0 
Catch-up to age 25 85.0 85.0 84.9 76.5 61.9 50.2 36.6 21.6 12.7 7.4 4.7 0.0 
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Scenario 17: 5-year efficacy vaccine with 2 boosters. Estimated situation in 30 
years. 
A 5-year efficacy vaccine including 2 boosters would maintain the maximum expected 
coverage up to age 25. At age 30, 62% of the women would still be protected and rate would 
drop to 21.4% at aged 40. With a catch-up to age 22 or 25, 8% of women aged 50 would still 
be protected (Figure 26 and Table 23). 
Figure 26. Estimated vaccination coverage by age, Switzerland. Scenario at 30 years for a 5-
year efficacy vaccine with 2 boosters. 
Table 23. Vaccination coverage using a 5-year efficacy vaccine with 2 boosters by age. 
Scenario at 30 years (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No catch-up 85.0 85.0 85.0 84.9 84.9 85.0 84.9 61.9 36.5 21.4 0.0 0.0 
Catch-up to age 18 85.0 85.0 85.0 85.0 85.0 85.0 85.0 61.9 36.5 21.5 0.0 0.0 
Catch-up to age 20 85.0 85.0 85.0 85.0 85.0 85.0 85.0 61.9 36.5 21.5 0.0 0.0 
Catch-up to age 22 85.0 85.0 85.0 85.0 85.0 85.0 85.0 61.9 36.5 21.5 7.9 0.0 
Catch-up to age 25 85.0 85.0 85.0 85.0 85.0 85.0 85.0 61.9 36.5 21.6 7.9 0.0 
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Scenario 18: 10-year efficacy vaccine without booster. Estimated situation in 30 
years. 
In the case of a vaccine with an efficacy of 10 years without booster, the maximum coverage 
would be sustained until age 22 and would still be of 62% at age 25. No catch-up or a catch-
up to ages 18 or 20 would reach a 13% coverage at age 40. A catch-up to age 22 or 25 would 
still maintain an 8% at age 50 (Figure 27 and Table 24). 
Figure 27. Estimated vaccination coverage by age, Switzerland. Scenario at 30 years for a 10-
year efficacy vaccine without booster. 
Table 24. Vaccination coverage using a 10-year efficacy vaccine without booster by age. 
Scenario at 30 years (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No catch-up 84.98 84.98 84.97 84.96 84.95 84.94 61.90 36.50 21.48 12.58 0.00 0.00 
Catch-up to age 18 84.99 84.99 84.98 84.98 84.97 84.96 61.92 36.54 21.53 12.58 0.00 0.00 
Catch-up to age 20 84.99 84.99 84.98 84.98 84.97 84.96 61.93 36.54 21.54 12.58 0.00 0.00 
Catch-up to age 22 84.99 84.99 84.98 84.98 84.97 84.97 61.93 36.54 21.54 12.58 7.90 0.00 
Catch-up to age 25 84.99 84.99 84.99 84.98 84.98 84.97 61.93 36.55 21.54 12.58 7.90 0.00 
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Scenario 19: 10-year efficacy vaccine with booster. Estimated situation in 30 years. 
In all cases, a 10-year efficacy vaccine with booster would maintain the maximum coverage 
of 85% up to age 30 years and a 36% coverage at age 40. A catch-up to age 22 or 25 would 
still keep a 23% coverage at age 50 (Figure 28 and Table 25). 
Figure 28. Estimated vaccination coverage by age, Switzerland. Scenario at 30 years for a 10-
year efficacy vaccine with booster. 
Table 25. Vaccination coverage using a 10-year efficacy vaccine with booster by age. 
Scenario at 30 years (in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No catch-up 84.99 84.98 84.97 84.97 84.96 84.97 84.95 84.89 61.74 36.28 0.00 0.00 
Catch-up to age 18 84.99 84.99 84.99 84.98 84.97 84.98 84.97 84.94 61.86 36.42 0.00 0.00 
Catch-up to age 20 84.99 84.99 84.99 84.98 84.98 84.98 84.98 84.95 61.87 36.44 0.00 0.00 
Catch-up to age 22 84.99 84.99 84.99 84.98 84.98 84.98 84.98 84.95 61.88 36.46 22.65 0.00 
Catch-up to age 25 84.99 84.99 84.99 84.98 84.98 84.99 84.98 84.95 61.89 36.47 22.65 0.00 
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Scenario 20: lifelong efficacy vaccine. Estimated situation in 30 years. 
After 30 years, a vaccine with lifelong efficacy would result in a 85% coverage up to age 40. 
A catch-up to age 22 or 25 would maintain a 72% coverage up to age 50 (Figure 29 and Table 
26). 
Figure 29. Estimated vaccination coverage by age, Switzerland. Scenario at 30 years for a 
lifelong efficacy vaccine. 
Table 26. Vaccination coverage using a lifelong efficacy vaccine by age. Scenario at 30 years 
(in percentage). 
Age (years) 12 14 16 18 20 22 25 30 35 40 50 60 
No catch-up 85.0 85.0 85.0 85.0 85.0 84.9 84.9 84.8 84.5 83.8 0.0 0.0 
Catch-up to age 18 85.0 85.0 85.0 85.0 85.0 85.0 84.9 84.9 84.7 83.8 0.0 0.0 
Catch-up to age 20 85.0 85.0 85.0 85.0 85.0 85.0 84.9 84.9 84.7 83.8 0.0 0.0 
Catch-up to age 22 85.0 85.0 85.0 85.0 85.0 85.0 85.0 84.9 84.7 83.8 72.2 0.0 
Catch-up to age 25 85.0 85.0 85.0 85.0 85.0 85.0 85.0 84.9 84.7 83.8 72.2 0.0 
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LIMITATIONS OF THE STUDY 
One limitation of this study is the scarcity of data concerning HPV infection in Switzerland. 
In fact, the only prevalence we have found is among a small (N=143) clinical sample of 
adolescents in Geneva (11). As a result, to construct our model we have been forced to rely on 
data from other countries, mainly the United States. Nevertheless, this fact should not 
influence much our results. 
A more important limitation is the fact that there are not a lot of data regarding the sexual 
behavior of Swiss. As an example, the only data that we have found for the number of sexual 
partners (33) include quite wide age ranges (17-20, 21-30, 31-45). We had then to divide the 
whole modelled period into only 8 age classes. This is clearly insufficient, especially after 30 
years, the consequences being a lower reliability of the exact HPV infection prevalence by 
age, and too abrupt changes in prevalence at the limit between age classes. 
This paucity of data has not allowed us to fully calibrate our model. Given these limitations, 
the model should not be used to predict the exact prevalence of HPV infection age by age. 
However, the model correctly reproduces the relative change in prevalence due to the 
implementation of different vaccination scenarios, so the results are correct in regard of the 
objective of the present study. 
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CONCLUSIONS 
Regarding the results of this report, the specific conclusions are: 
7. Overall, and both from the reduction of the infection rate and the vaccination coverage 
rate points of view, any catch-up is better than no catch-up at all. However, our model 
indicates that a catch-up to age 18 or to age 20 would represent a very small 
difference. The same would be true between a catch-up to age 22 or to age 25, 
although the later would result in better coverage and infection rates than the former. 
This statement is independent of the efficacy of the vaccine and of whether or not a 
booster is implemented. 
8. In the case of a 5-year efficacy vaccine (which is the current case as far as we know) 
without booster, the maximum expected vaccination coverage of 85% would only be 
maintained up to age 16/17, both in a 15 or 30-year horizon and independently of 
whether there is a catch-up or not. Under the same circumstances, half of the women 
aged 22 would still be protected. In a 15-year perspective, some coverage (23%) 
would still be expected among women aged 30 with a catch-up to age 18/20, while 
with a catch-up to age 22/25 the same coverage would be observed up to age 35. In a 
30-year perspective, the same coverage rate would be observed up to age 40 (7%) 
independently of catch-up. In the case of a catch-up to age 22/25, the coverage would 
be extended to age 50, although it would be minimal (<5%). 
9. In the case of a 5-year efficacy vaccine including 2 boosters (at ages 17 and 22), a 
85% vaccination coverage would be assured, in any case, up to age 25. For a 15-year 
horizon, any catch-up would still maintain a 50% protection among women aged 30. 
A catch-up to age 22/25 would still maintain a protection slightly below 40% among 
women aged 35. In 30 years, this vaccination option would still maintain protection 
rates of 62%, 36% and 21% at, respectively, ages 30,35 and 40 years independently of 
catch-up. A catch-up to age 22/25 would still maintain some coverage (8%) at age 50. 
10. In the case of a 10-year efficacy vaccine without booster (that could be overlapped to a 
5-year efficacy vaccine with one booster at age 17), the maximum expected coverage 
would be maintained up to age 22 and would still be slightly above 60% at age 25 in 
any case. For a 15-year horizon, any catch-up would imply a coverage just under 40% 
at age 30 and also at age 35 but in this later case only for those with a catch-up to age 
22/25. In 30 years, independently of catch-up, a vaccine coverage of 36, 21 and 12%, 
respectively, would be expected for ages 30, 35 and 40. A catch-up to ages 22/25 
would only add a small coverage (8%) at age 50. 
11. In the case of a 10-year efficacy vaccine that would include a booster 10 years later 
(age 22), the situation is different depending on the chosen horizon. In 15 years, 
maximum coverage up to age 25 would be assured in any case. Any catch-up would 
result in a 67% coverage at age 30, while a catch-up to ages 22/25 would imply a 65% 
coverage at age 35. In a 30 years perspective, the maximum projected coverage would 
be maintained up to age 30. Any option would result in a 62% coverage at age 35 and 
36% at age 40. With a catch-up to ages 22/25, 23% of the women aged 50 would still 
be protected. 
12. In the case of a lifelong efficacy vaccine, in 15-years time the projected maximum 
coverage would reach age 25. Any catch-up would still protect 74% of women aged 
30 and a catch-up to ages 22/25 would result in a 72% coverage at age 35. In 30 years, 
any vaccination option would result in a maximum expected coverage up to age 40, 
while a catch-up to ages 22/25 would add a 72% coverage at age 50. 
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RECOMMENDATIONS 
At the present time it is difficult to give clear recommendations about the best vaccination 
program option because we lack information on one of the main factors influencing this 
decision: the duration of the vaccine efficacy. To date, there is only evidence of a 5 year 
efficacy (1;2). 
From this standpoint, the current recommendation would be to implement a vaccination 
program among girls aged 12 years with a catch-up to age 22 years, since a longer catch-up 
time (up to age 25) would mean an extremely small difference. 
However, this recommendation should be reviewed in five years. At that point in time, we 
will be facing two possible situations: 
3. There will be evidence of a longer duration of the vaccine’s efficacy (up to 10 years) 
and no changes in the vaccination program would be needed. 
4. There will be no evidence of an efficacy duration beyond 5 years and a decision 
regarding booster implementation will need to be taken. 
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